Related Experiment Video

Updated: Mar 8, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.3K

New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy

Kevin Zarrabi1, Chunhui Fang1, Shenhong Wu2,3

  • 1Department of Medicine, Stony Brook University Hospital, 9447 Suny, Stony Brook, NY, 11794-9447, USA.

Journal of Hematology & Oncology
|February 4, 2017
PubMed

Insights

Advanced renal cell carcinoma (RCC) treatment is shifting. New agents like cabozantinib, nivolumab, and lenvatinib show improved survival after anti-angiogenesis therapy resistance.

Area of Science:

  • Oncology
  • Nephrology

Background:

  • Angiogenesis is crucial in advanced renal cell carcinoma (RCC) progression.
  • Anti-angiogenesis therapies are primary treatments for metastatic RCC.
  • Resistance to anti-angiogenesis therapy is common, necessitating new treatment strategies.

Purpose of the Study:

  • To review current and newly approved agents for advanced RCC.
  • To discuss the rationale and clinical studies supporting their use.
  • To provide perspective on treatment paradigm shifts in advanced RCC.

Main Methods:

  • Literature review of clinical trials and drug approvals.
  • Analysis of therapeutic strategies for advanced RCC.
  • Summary of agents used after anti-angiogenesis therapy failure.

Main Results:

  • Axitinib and everolimus are established treatments post-anti-angiogenesis therapy.
  • New agents including cabozantinib, nivolumab, and lenvatinib demonstrate improved overall survival compared to everolimus.
  • These agents represent a significant advancement in managing advanced RCC.

Conclusions:

  • The treatment landscape for advanced RCC is evolving rapidly.
  • Newly approved agents offer improved outcomes for patients resistant to prior therapies.
  • Understanding resistance mechanisms guides the development of novel therapeutic approaches.
Keywords:
Anti-angiogenesisCabozantinibLenvatinibNivolumabRenal cell carcinoma

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.3K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.5K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
609
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
519